These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 34868984)

  • 1. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
    Peng Y; Mei W; Ma K; Zeng C
    Front Oncol; 2021; 11():763790. PubMed ID: 34868984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
    Chen H; Zhou Q
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assay.
    Hashimoto T; Nakamura Y; Oki E; Kobayashi S; Yuda J; Shibuki T; Bando H; Yoshino T
    Int J Clin Oncol; 2024 May; 29(5):495-511. PubMed ID: 38551727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review.
    Zhu L; Xu R; Yang L; Shi W; Zhang Y; Liu J; Li X; Zhou J; Bing P
    Front Genet; 2023; 14():1172108. PubMed ID: 37636270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
    Shields MD; Chen K; Dutcher G; Patel I; Pellini B
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease.
    Moding EJ; Nabet BY; Alizadeh AA; Diehn M
    Cancer Discov; 2021 Dec; 11(12):2968-2986. PubMed ID: 34785539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
    Kasi PM; Fehringer G; Taniguchi H; Starling N; Nakamura Y; Kotani D; Powles T; Li BT; Pusztai L; Aushev VN; Kalashnikova E; Sharma S; Malhotra M; Demko ZP; Aleshin A; Rodriguez A; Billings PR; Grothey A; Taieb J; Cunningham D; Yoshino T; Kopetz S
    JCO Precis Oncol; 2022 Mar; 6():e2100181. PubMed ID: 35263168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer.
    Fang X; Yu S; Jiang Y; Xiang Y; Lu K
    Front Oncol; 2022; 12():1027664. PubMed ID: 36387176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors.
    Larribère L; Martens UM
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
    Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
    Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
    Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
    BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
    Chakrabarti S; Kasi AK; Parikh AR; Mahipal A
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
    Chae YK; Oh MS
    J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer.
    Tang L; Li R; Wen H; Zhou Q; Xu C
    Chin Med J Pulm Crit Care Med; 2023 Dec; 1(4):207-214. PubMed ID: 39171282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review.
    Chakrabarti S; Xie H; Urrutia R; Mahipal A
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
    Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
    Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid Biopsies for Monitoring Medulloblastoma: Circulating Tumor DNA as a Biomarker for Disease Progression and Treatment Response.
    Buccilli B; Rodriguez Molina MA; Redrovan Palomeque DP; Herrera Sabán CA; C Caliwag FM; Contreras Flores CJS; Abeysiriwardana CWJ; Diarte E; Arruarana VS; Calderon Martinez E
    Cureus; 2024 Jan; 16(1):e51712. PubMed ID: 38313884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma.
    Fu Y; Xu Y; Liu W; Zhang J; Wang F; Jian Q; Huang G; Zou C; Xie X; Kim AH; Mathios D; Pang F; Li F; Wang K; Shen J; Yin J
    EClinicalMedicine; 2024 Jul; 73():102697. PubMed ID: 39022798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.